{{Rsnum
|rsid=889299
|Gene=SCNN1B
|Chromosome=16
|position=23370593
|Orientation=minus
|GMAF=0.2677
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=SCNN1B
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 57.1 | 36.6 | 6.2
| HCB | 41.9 | 46.3 | 11.8
| JPT | 53.6 | 38.4 | 8.0
| YRI | 51.0 | 39.5 | 9.5
| ASW | 61.4 | 38.6 | 0.0
| CHB | 41.9 | 46.3 | 11.8
| CHD | 0.0 | 0.0 | 0.0
| GIH | 61.2 | 31.6 | 7.1
| LWK | 45.9 | 44.0 | 10.1
| MEX | 62.1 | 29.3 | 8.6
| MKK | 54.5 | 36.4 | 9.1
| TSI | 67.6 | 27.5 | 4.9
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs889299
|Name_s=
|Gene_s=SCNN1B
|Feature=
|Evidence=PubMed ID:18004211
|Annotation=This variant in the SCNN1B gene showed the most significant association with fluid retention/oedema in participants diagnosed with T2DM receiving farglitazar plus insulin or glyburide combination therapies. But this association has low penetrance in the fluid retention/oedema case population reflecting that SCNN1B variation may be only one of the covariates that contribute to the development of PPAR[gamma]-induced fluid retention.
|Drugs=glibenclamide; insulin-glargine
|Drug Classes=
|Diseases=Diabetes Mellitus, Type 2
|Curation Level=Curated
|PharmGKB Accession ID=PA162355504
}}

{{PMID Auto
|PMID=18184758
|Title=Plasma potassium level is associated with common genetic variation in the beta-subunit of the epithelial sodium channel.
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs889299
|overall_frequency_n=34
|overall_frequency_d=128
|overall_frequency=0.265625
|n_genomes=25
|n_genomes_annotated=0
|n_haplomes=30
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}